ELMO3 Antibody

Code CSB-PA846590LA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human melanoma using CSB-PA846590LA01HU at dilution of 1:100

  • Immunofluorescent analysis of MCF-7 cells using CSB-PA846590LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) ELMO3 Polyclonal antibody
Uniprot No.
Target Names
ELMO3
Alternative Names
CED 12 antibody; Ced 12 homolog 3 antibody; CED12 antibody; ELMO 3 antibody; ELMO3 antibody; ELMO3_HUMAN antibody; Engulfment and cell motility 3 antibody; Engulfment and cell motility protein 3 antibody; FLJ13824 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Engulfment and cell motility protein 3 protein (464-596AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The ELMO3 Antibody (Product code: CSB-PA846590LA01HU) is Non-conjugated. For ELMO3 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA846590LB01HU ELMO3 Antibody, HRP conjugated ELISA
FITC CSB-PA846590LC01HU ELMO3 Antibody, FITC conjugated
Biotin CSB-PA846590LD01HU ELMO3 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, IHC, IF
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
IF 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Acts in association with DOCK1 and CRK. Was initially proposed to be required in complex with DOCK1 to activate Rac Rho small GTPases. May enhance the guanine nucleotide exchange factor (GEF) activity of DOCK1.
Gene References into Functions
  1. the silencing of ELMO3 inhibited cell proliferation, invasion, metastasis, and F-actin polymerization, and induced Gap 1 (G1) phase cell cycle arrest, demonstrating that ELMO3 is involved in the processes of growth, invasion and metastasis of Colorectal Cancer PMID: 27999268
  2. The purpose of this study was to asses ELMO3 expression in postoperatively irradiated head and neck squamous cell carcinoma patients. PMID: 28039609
  3. The over-expression of ELMO3 was a potential diagnostic and prognostic marker for non-small cell lung cancer. PMID: 26191257
  4. The present study reports the first characterization of the ELMO3 promoter and suggests a significant role of CDX2 in the basal transcriptional regulation of the intestine-specific expression of ELMO3, possibly through interaction with SP1. PMID: 20127720
Subcellular Location
Cytoplasm.
Database Links

HGNC: 17289

OMIM: 606422

KEGG: hsa:79767

STRING: 9606.ENSP00000377566

UniGene: Hs.377416

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*